OTR-AC (MK-29, ostarina-O-acetato)

Descripción

Descripción general del producto:

Este producto es una formulación líquida que contiene 50 ml of solution at a concentration of 10 mg/ml, providing a total of 50 x 10 mg (or 500 mg per vial).

Información química:

• Peso molecular: 453,498 g/mol
• Fórmula molecular: C21H18F3N03S2

Solubilidad:
The product is soluble in poliglicoles, making it suitable for various application methods where such solvents are applicable.

Pureza:
The substance boasts a high purity of >99%, ensuring high-quality performance in its intended applications.

Condiciones de almacenamiento:
To maintain the product’s efficacy, it should be stored at a temperature of 20℃ and can remain stable for a period of up to 2 años en condiciones adecuadas de almacenamiento.

Farmacocinética:
– Vida media: The half-life of the compound is approximately 24 horas, indicating how long it remains active in the system before being metabolized or eliminated.

Información reglamentaria:
– Número CAS: 317318-70-0

Nota: The information provided is based on data available up to October 2023 and has been last modified on 1 de febrero de 2024. Always refer to current guidelines and safety data sheets when handling chemicals.

Senza un contesto specifico, è difficile associare questi dati a un integratore alimentare specifico. Tuttavia, dal peso molecolare e dalla formula molecolare, posso ipotizzare che si riferiscono a GW501516, noto anche come Cardarine o Endurobol.

Qui ci sono alcune fonti di riferimento scientifico riguardanti GW501516 anche se non si tratta di un supplemento alimentare ma di un composto per la ricerca tuttavia a causa del suo uso diffuso nel mondo del fitness e del body building molte persone fanno confusione.

1. Miner, J. N., & Hong, M.-H. (2007). Agonists of the peroxisome proliferator-activated receptor (PPAR-delta). US7223756B2. U.S. Patent and Trademark Office. Enlace
2. Liu, D., Wang, L., & Wang, Z. (2018). PPARδ agonist GW501516 inhibits PDGF-stimulated pulmonary arterial smooth muscle cell function related to pathological vascular remodeling. Biomedicine & Pharmacotherapy, 97, 458–467. Enlace
3. Sprecher, D. L., Massien, C., Pearce, G., Billin, A. N., Perlstein, I., Willson, T. M., Hassall, D. G., Ancellin, N., Patterson, S. D., Lobe, D. C., & Johnson, T. G. (2007). Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist. Arteriosclerosis, Thrombosis, and Vascular Biology, 27(2), 359–365. Enlace
4. Smith, R. V., Havens, A. M., & Nebert, D. W. (2017). The PPAR-δ agonist GW501516 prevents the development of osteoarthritis in mouse. Current Research